142 related articles for article (PubMed ID: 24882148)
1. [LDL-cholesterol control in patients with genetic dyslipidemia followed up by Lipid and Vascular Risk Units of the Spanish Society of Arteriosclerosis].
Lahoz C; Mostaza JM; Pintó X; de la Cruz JJ; Banegas JR; Pedro-Botet J;
Clin Investig Arterioscler; 2015; 27(1):1-8. PubMed ID: 24882148
[TBL] [Abstract][Full Text] [Related]
2. [Achievement of low-density lipoprotein cholesterol therapeutic goal in lipid and vascular risk units of the Spanish Arteriosclerosis Society].
Pedro-Botet J; Mostaza JM; Pintó X; Banegas JR;
Clin Investig Arterioscler; 2013; 25(4):155-63. PubMed ID: 24041476
[TBL] [Abstract][Full Text] [Related]
3. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
[TBL] [Abstract][Full Text] [Related]
4. Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia.
Menzin J; Aggarwal J; Boatman B; Yu J; Stern K; Harrison DJ; Patel JG
J Manag Care Spec Pharm; 2017 Dec; 23(12):1270-1276. PubMed ID: 29172973
[TBL] [Abstract][Full Text] [Related]
5. Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU).
Masana L; López Miranda J; Civeira F; Reinares L; Guijarro C; Plana N; Cuenca R; Sánchez D; Hernández JL; Andrés R; Blanco A; Villamayor S
Clin Investig Arterioscler; 2020; 32(5):183-192. PubMed ID: 32317124
[TBL] [Abstract][Full Text] [Related]
6. [Update of planning tables of cholesterol-lowering therapy orientated to achieve LDL therapeutic targets].
Masana L; Plana N
Clin Investig Arterioscler; 2015; 27(3):138-43. PubMed ID: 25865752
[TBL] [Abstract][Full Text] [Related]
7. [Screening for familial hypercholesterolemia from low-density lipoprotein cholesterol levels at admission in the coronary care unit].
Chemaly P; Nallet O; Delarche N; Legagneur C; Boulestreau R; Reibel I; Palette C; Grenier A; Courtade H; Beaune G; Belle L; Georges JL
Ann Cardiol Angeiol (Paris); 2018 Nov; 67(5):300-309. PubMed ID: 30290906
[TBL] [Abstract][Full Text] [Related]
8. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
[TBL] [Abstract][Full Text] [Related]
9. A 10-year experience using combined lipid-lowering pharmacotherapy in children and adolescents.
Araujo MB; Pacce MS
J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1285-1291. PubMed ID: 27718491
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
Li L; Zhang M; Su F; Li Y; Shen Y; Shen J; Zhang D
Lipids Health Dis; 2015 Feb; 14():10. PubMed ID: 25879728
[TBL] [Abstract][Full Text] [Related]
11. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.
Elis A; Zhou R; Stein EA
Am J Cardiol; 2011 Jul; 108(2):223-6. PubMed ID: 21545982
[TBL] [Abstract][Full Text] [Related]
12. Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort.
Peretti N; Vimont A; Mas E; Lemale J; Reynaud R; Tounian P; Poinsot P; Restier L; Paillard F; Pradignac A; Pucheu Y; Rabès JP; Bruckert E; Gallo A; Béliard S
Arch Pediatr; 2024 Apr; 31(3):188-194. PubMed ID: 38538465
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia.
Kawashiri MA; Nohara A; Noguchi T; Tada H; Nakanishi C; Mori M; Konno T; Hayashi K; Fujino N; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
Am J Cardiol; 2012 Feb; 109(3):364-9. PubMed ID: 22112743
[TBL] [Abstract][Full Text] [Related]
14. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of ezetimibe in vascular risk units].
Díaz Díaz JL; Suárez Tembra M; Díaz Peromingo JA; Pena Seijo M; Martínez Ramonde T; Pose Reino A
Rev Clin Esp; 2011 Jun; 211(6):283-90. PubMed ID: 21481368
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients.
Davidson M
Clin Ther; 2013 Aug; 35(8):1247-52. PubMed ID: 23916045
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
Bays HE; Davidson MH; Massaad R; Flaim D; Lowe RS; Tershakovec AM; Jones-Burton C
Am J Cardiol; 2011 Aug; 108(4):523-30. PubMed ID: 21596364
[TBL] [Abstract][Full Text] [Related]
19. [Unmet needs: patients with statin intolerance or familial hypercholesterolemia].
Masana L; Civeira F
Clin Investig Arterioscler; 2016 May; 28 Suppl 2():22-30. PubMed ID: 27888902
[TBL] [Abstract][Full Text] [Related]
20. Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia.
Taylan C; Schlune A; Meissner T; Ažukaitis K; Udink Ten Cate FE; Weber LT
J Clin Lipidol; 2016; 10(6):1303-1310. PubMed ID: 27919346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]